Cite
Vallerio P, Orenti A, Tosi F, et al. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2021;7(1):100338doi: 10.1016/j.esmoop.2021.100338.
Vallerio, P., Orenti, A., Tosi, F., Maistrello, M., Palazzini, M., Cingarlini, S., Colombo, P., Bertuzzi, M., Spina, F., Amatu, A., Lombardo, R., Prata, I., Scaglione, F., Vighi, G. D., Severgnini, B., Siena, S., Giannattasio, C., Boracchi, P., & Sartore-Bianchi, A. (2021). Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO open, 7(1), 100338. https://doi.org/10.1016/j.esmoop.2021.100338
Vallerio, P, et al. "Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management." ESMO open vol. 7,1 (2021): 100338. doi: https://doi.org/10.1016/j.esmoop.2021.100338
Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, Colombo P, Bertuzzi M, Spina F, Amatu A, Lombardo R, Prata I, Scaglione F, Vighi GD, Severgnini B, Siena S, Giannattasio C, Boracchi P, Sartore-Bianchi A. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2021 Dec 14;7(1):100338. doi: 10.1016/j.esmoop.2021.100338. Epub 2021 Dec 14. PMID: 34920290; PMCID: PMC8685997.
Copy
Download .nbib